AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Filing of Public Announcement for Buyback of Fully Paid -up Equity Shares of Aarti Drugs Limited pursuant to the provisions of Regulation 7(i) of SEBI (Buyback of Securities) Regulations, 2018, as amended ('Buyback Regulation') Aarti Drugs Ltd - 524348 - Corporate Action-Updates on Buy back
Please find enclosed a certified true copy of the Board Resolution dated March 19, 2021 approving the captioned Buyback, as required under Regulation 5 (vii) of the Buyback Regulations. AARTI DRUGS LTD. - 524348 - Buyback Offer
Inga Ventures Pvt Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Public announcement for the attention of Equity Shareholders/ Beneficial owners of Equity Shares of Aarti Drugs Ltd ("Target Company") for the Buyback of Equity Shares through a Tender Offer under Securities and Exchange Board of India (Buy Back of Securities) Regulations, 2018, as amended ("Buyback Regulations"). Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending the Investor Conference Aarti Drugs Rallies After Board Approves Rs 60 Crore Share Buyback Plan
Aarti Drugs share buyback price of Rs 1,000 is at a premium of 46 per cent to its yesterday's closing price of Rs 683. AARTI DRUGS LTD. - 524348 - Board approves Buy back of equity shares
Aarti Drugs Ltd has informed BSE about Outcome of Board Meeting held on March 19, 2021. AARTI DRUGS LTD. - 524348 - The Board Of Directors Has Determined The Record Date For The Proposed Buyback As April 1, 2021 ('Record Date').
The Board of Directors has determined the Record Date for the proposed Buyback as April 1, 2021 ('Record Date'). AARTI DRUGS LTD. - 524348 - Outcome Of Board Meeting Held Today I.E. March 19, 2021 Of Aarti Drugs Limited ('Company')
Further to our intimation dated March 16, 2021 and in terms of Regulation 30 and 42(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 9(i) of Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018, as amended ('Buyback Regulations'), we wish to inform you that the Board of Directors at its meeting held today has approved the Buyback. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates. Aarti Drugs' board to consider shares buyback later this week
Shares of Aarti Drugs were trading 3.15 per cent higher at 688.60 apiece on BSE.